KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsCost Of Goods SoldCost Of Goods Sold By SegmentEmployee StatisticsGross Margin %Gross Margin By Segment %Gross ProfitGross Profit By SegmentIncome (Loss) Before Income Tax By RegionLong Lived Assets By Geography AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Income (Loss) By SegmentOperating Income (Loss) By Segment AnnualOperating Margin By Segment %Operating Margin By Segment Annual %Opex As A % Of Total Revenue %OPEX SegregationProperty, Plant, And Equipment, NetRevenue By Category AvkareRevenue By Category Avkare AnnualRevenue By Category GenericsRevenue By Category Generics AnnualRevenue By Category SpecialtyRevenue By Category Specialty AnnualRevenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Gross Profit (2017 - 2025)

Amneal Pharmaceuticals has reported Gross Profit over the past 9 years, most recently at $297.2 million for Q4 2025.

  • Quarterly results put Gross Profit at $297.2 million for Q4 2025, up 13.05% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (up 9.1% YoY), and the annual figure for FY2025 was $1.1 billion, up 9.1%.
  • Gross Profit for Q4 2025 was $297.2 million at Amneal Pharmaceuticals, up from $274.0 million in the prior quarter.
  • Over the last five years, Gross Profit for AMRX hit a ceiling of $297.2 million in Q4 2025 and a floor of $166.4 million in Q4 2021.
  • Median Gross Profit over the past 5 years was $217.7 million (2022), compared with a mean of $225.4 million.
  • Biggest five-year swings in Gross Profit: soared 48.6% in 2021 and later dropped 11.87% in 2023.
  • Amneal Pharmaceuticals' Gross Profit stood at $166.4 million in 2021, then increased by 29.44% to $215.4 million in 2022, then decreased by 11.87% to $189.8 million in 2023, then skyrocketed by 38.48% to $262.9 million in 2024, then rose by 13.05% to $297.2 million in 2025.
  • The last three reported values for Gross Profit were $297.2 million (Q4 2025), $274.0 million (Q3 2025), and $286.3 million (Q2 2025) per Business Quant data.